Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Horvath, K; Bock, G; Regittnig, W; Bodenlenz, M; Wutte, A; Plank, J; Magnes, C; Sinner, F; Fürst-Recktenwald, S; Theobald, K; Pieber, TR.
Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study.
Diabetes Obes Metab. 2008; 10(6):484-491
Doi: 10.1111/j.1463-1326.2007.00734.x
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Horvath Karl
- Co-Autor*innen der Med Uni Graz
- Pieber Thomas
- Regittnig Werner
- Sinner Frank Michael
- Treiber Gerlies
- Weiss Manfred
- Wutte Andrea-Maria
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To compare the end-organ metabolic effects of insulin glulisine (glulisine), insulin lispro (lispro) and regular human insulin (RHI) in patients with type 1 diabetes mellitus. Eighteen patients with type 1 diabetes mellitus (mean age 36.9 +/- 8.6 years, BMI 23.6 +/- 2.8 kg/m(2), haemoglobin A(1c) 7.4 +/- 0.9%) were randomized in this single-centre, double-blind, three-period cross-over, standard Latin-square, euglycaemic glucose clamp trial. Patients received sequential, primed stepwise intravenous infusions of glulisine, lispro or RHI (infusion rates were increased in a stepwise manner from an initial rate of 0.33 [180 min] to 0.66 [180 min] and 1.00 [180 min] mU/kg/min). The primary variables were the suppression of endogenous glucose production (S(EGP)) and glucose uptake (GU). Mean basal endogenous glucose production (EGP) was 1.88, 2.12 and 2.12 mg/kg/min for glulisine, lispro and RHI respectively. Mean (+/-s.e.) maximum absolute S(EGP) (adjusted for basal EGP) was -1.64 +/- 0.06, -1.72 +/- 0.05 and -1.56 +/- 0.05 mg/kg/min respectively. Mean (+/-s.e.) maximum absolute increase in GU (adjusted for basal GU) was 6.46 +/- 0.26, 6.23 +/- 0.24 and 6.72 +/- 0.24 mg/kg/min respectively. There were no clinically relevant differences between the three insulin treatments with respect to serum insulin, free fatty acid (FFA), glycerol or lactate levels. No serious adverse events and no episodes of severe hypoglycaemia were reported. This study shows that glulisine, lispro and RHI have similar effects on S(EGP), GU, FFA, glycerol and lactate levels, providing evidence for similar end-organ metabolic effects.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Blood Glucose - drug effects
- Blood Glucose - metabolism
- Cross-Over Studies -
- Diabetes Mellitus, Type 1 - blood
- Diabetes Mellitus, Type 1 - metabolism
- Double-Blind Method -
- Fatty Acids, Nonesterified - blood
- Female -
- Glucose Clamp Technique - methods
- Glycerol - blood
- Humans -
- Hypoglycemic Agents - pharmacokinetics
- Infusions, Intravenous -
- Insulin - analogs & derivatives
- Insulin - blood
- Insulin - pharmacokinetics
- Insulin Lispro -
- Lactic Acid - blood
- Male -
- Middle Aged -
- Find related publications in this database (Keywords)
- euglycaemic glucose clamp
- glulisine
- lispro